<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893631</url>
  </required_header>
  <id_info>
    <org_study_id>AGR_2015_25</org_study_id>
    <nct_id>NCT02893631</nct_id>
  </id_info>
  <brief_title>Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke</brief_title>
  <acronym>HEMOLYSE</acronym>
  <official_title>Assessment of Hemostasis Disorders in Tissue Plasminogen Activator Treated (rtPA-treated) Patients Requiring Endovascular Treatment for Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Stroke treatment includes thrombolysis, thrombectomy for patients with proximal artery&#xD;
      occlusion and sometimes neurosurgery. It rises questions regarding hemostasis: thrombolysis&#xD;
      induces fibrinolysis but its effects on coagulation, fibrinogen and platelets and duration of&#xD;
      these effects are unknown. Thus management of antithrombotics and hemostasis during&#xD;
      thrombectomy and surgery is an issue.&#xD;
&#xD;
      Objectives : to describe thrombolysis-induced hemostatic disorders (fibrinolysis,&#xD;
      coagulation, fibrinogen, platelets) in patients requiring thrombectomy for stroke and to&#xD;
      evaluate the time required for the normalization of these disorders.&#xD;
&#xD;
      Methods : Observational monocentric study including rtPA-treated patients requiring&#xD;
      endovascular treatment for stroke. Blood sampling within the first 48 hours after rtPA&#xD;
      administration to assess of fibrinolysis, coagulation and platelet functions with point of&#xD;
      care devices and specific laboratory tests. Record of clinical and biological data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">November 21, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fibrinolysis activity</measure>
    <time_frame>until normalization of fibrinolytic activity, up to 48 hours</time_frame>
    <description>Time required for normalization of fibrinolysis</description>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stroke, Acute</condition>
  <eligibility>
    <study_pop>
      <textblock>
        rtPA-treated patients requiring endovascular treatment for ischemic stroke&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient over 18&#xD;
&#xD;
          -  treatment with rtPA for an acute stroke&#xD;
&#xD;
          -  endovascular treatment required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  opposition to participate in the study&#xD;
&#xD;
          -  long term anticoagulant-treated patient&#xD;
&#xD;
          -  pregnant patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claire NGHE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

